Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER)

Abstract

In a multinational, double‐blind, placebo‐controlled trial (NCT00474058), 287 subjects with Parkinson's disease (PD) and unsatisfactory early‐morning motor symptom control were randomized 2:1 to receive rotigotine (2–16 mg/24 hr [n = 190]) or placebo (n = 97). Treatment was titrated to optimal dose over 1–8 weeks with subsequent dose maintenance for 4 weeks. Early‐morning motor function and nocturnal sleep disturbance were assessed as coprimary efficacy endpoints using the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Examination) measured in the early morning prior to any medication intake and the modified Parkinson's Disease Sleep Scale (PDSS‐2) (mean change from baseline to end of maintenance [EOM], last observation carried forward). At EOM, mean UPDRS Part III score had decreased by −7.0 points with rotigotine (from a baseline of 29.6 [standard deviation (SD) 12.3] and by −3.9 points with placebo (baseline 32.0 [13.3]). Mean PDSS‐2 total score had decreased by −5.9 points with rotigotine (from a baseline of 19.3 [SD 9.3]) and by −1.9 points with placebo (baseline 20.5 [10.4]). This represented a significantly greater improvement with rotigotine compared with placebo on both the UPDRS Part III (treatment difference: −3.55 [95% confidence interval (CI) −5.37, −1.73]; P = 0.0002) and PDSS‐2 (treatment difference: −4.26 [95% CI −6.08, −2.45]; P < 0.0001). The most frequently reported adverse events were nausea (placebo, 9%; rotigotine, 21%), application site reactions (placebo, 4%; rotigotine, 15%), and dizziness (placebo, 6%; rotigotine 10%). Twenty‐four‐hour transdermal delivery of rotigotine to PD patients with early‐morning motor dysfunction resulted in significant benefits in control of both motor function and nocturnal sleep disturbances. © 2010 Movement Disorder Society

Shown for reading. Its publisher allows quoting it, not republishing it.

References 30

1. 1.

   Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol. 2008;15(Suppl 1):14-20.

   Not in our library10.1111/j.1468-1331.2008.02056.x

2. 2.

   Wolters EC, Tesselaar HJ. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. J Neurol. 1996;243:235-240.

   Not in our library10.1007/bf00868520

3. 3.

   Högl B, Rothdach A, Wetter TC, Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology. 2003;28:1866-1870.

   Not in our library10.1038/sj.npp.1300250

4. 4.

   Romigi A, Stanzione P, Marciani MG, et al. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study. J Neural Transm. 2006;113:1909-1913.

   Not in our library10.1007/s00702-006-0490-x

5. 5.

   Rektorova I, Balaz M, Svatova J, et al. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol. 2008;31:261-266.

   Not in our library10.1097/wnf.0b013e31815d25ce

6. 6.

   Grandas F, Martínez-Martín P, Linazasoro G, The STAR Multicenter Study Group. Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study. J Neurol. 1998;245(Suppl 1):S31-S33.

   Not in our library10.1007/pl00007736

7. 7.

   Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin Pharmacother. 2009;10:677-691.

   Not in our library10.1517/14656560902746041

8. 8.

   Pham DQ, Nogid A. Rotigotine transdermal system for the treatment of Parkinson's disease. Clin Ther. 2008;30:813-824.

   Not in our library10.1016/j.clinthera.2008.05.007

9. 9.

   Pahwa R, Poewe W, Lyons KE, Boroojerdi B. Changes in early morning motor status following adjunctive treatment of advanced Parkinson's disease with rotigotine transdermal system in two large, placebo-controlled trials (PREFER and CLEOPATRA-PD). Mov Disord. 2009;24:S280.

   Not in our library

10. 10.

    Martínez-Martín P, Gil-Nagel A, Gracia LM, Gómez JB, Martinez-Sarriés J, Bermejo F, The Cooperative Multicentric Group. Unified Parkinson's Disease Rating Scale characteristics and structure. Mov Disord. 1994;9:76-83.

    Not in our library10.1002/mds.870090112

11. 11.

    Trenkwalder C, Kohnen R, Högl B, et al. Parkinson disease sleep scale—Validation of the Revised Version PDSS-2. Mov Disord. 2010.

    Not in our library10.1002/mds.23476

12. 12.

    Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S. Sleep disorders in Parkinson's disease. J Neurol. 1998;245(Suppl 1):S15-8.

    Not in our library10.1007/pl00007731

13. 13.

    Martinez-Martin P, Rodriguez-Blazquez C, Abe K, et al. International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. Neurology. 2009;73:1584-1591.

    Not in our library10.1212/wnl.0b013e3181c0d416

14. 14.

    Visser M, Leentjens AF, Marinus J, Stiggelbout AM, van Hilten JJ. Reliability and validity of the Beck depression inventory in patients with Parkinson's disease. Mov Disord. 2006;21:668-672.

    Not in our library10.1002/mds.20792

15. 15.

    Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol. 1998;245(Suppl 1):S10-4.

    Not in our library10.1007/pl00007730

16. 16.

    Christenson GA, Faber RJ, de Zwaan M, et al. Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry. 1994;55:5-11.

    Not in our library

17. 17.

    Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24:1468-1474.

    Not in our library10.1002/mds.22596

18. 18.

    Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68:1108-1115.

    Not in our library10.1212/01.wnl.0000258660.74391.c1

19. 19.

    A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol. 2003;60:1721-1728.

    Not in our library10.1001/archneur.60.12.1721

20. 20.

    Giladi N, Mair KJ, Badenhorst F, et al. Effects of rotigotine transdermal patch on early morning motor function, sleep quality, and daytime sleepiness in patients with idiopathic Parkinson's disease. Results of a multicenter, multinational trial. Eur J Neurol. 2006;13(Suppl. 2):74[P1127].

    Not in our library

21. 21.

    Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2002;73:629-635.

    Not in our library10.1136/jnnp.73.6.629

22. 22.

    Martínez-Martín P, Salvador C, Menéndez-Guisasola L, et al. Parkinson's disease sleep scale: validation study of a Spanish version. Mov Disord. 2004;19:1226-1232.

    Not in our library10.1002/mds.20144

23. 23.

    Margis R, Donis K, Schönwald SV, et al. Psychometric properties of the Parkinson's disease sleep scale—Brazilian version. Parkinsonism Relat Disord. 2009;15:495-499.

    Not in our library10.1016/j.parkreldis.2008.12.008

24. 24.

    Uemura Y, Nomura T, Inoue Y, et al. Validation of the Parkinson's disease sleep scale in Japanese patients: a comparison study using the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale and Polysomnography. J Neurol Sci. 2009;287:36-40.

    Not in our library10.1016/j.jns.2009.09.015

25. 25.

    Wang G, Cheng Q, Zeng J, et al. Sleep disorders in Chinese patients with Parkinson's disease: validation study of a Chinese version of Parkinson's disease sleep scale. J Neurol Sci. 2008;271:153-157.

    Not in our library10.1016/j.jns.2008.04.008

26. 26.

    Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol. 2008;31:151-166.

    Not in our library10.1097/wnf.0b013e31814b113e

27. 27.

    Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord. 2005;20:151-157.

    Not in our library10.1002/mds.20276

28. 28.

    Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: Treatment of nonmotor symptoms of Parkinson disease. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74:924-931.

    Not in our library10.1212/wnl.0b013e3181d55f24

29. 29.

    Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464-474.

    Not in our library10.1016/s1474-4422(09)70068-7

30. 30.

    Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf. 2003;26:439-444.

    Not in our library10.2165/00002018-200326060-00005

Cited by papers we hold 1

• Insomnia in neurological diseases · 2021
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.